She is also a member of Xeris advisory board
There were two coprimary composite CV endpoints
doi: 10.1016/j.eprac.2021.04.001 Summary Keywords semaglutide, overweight, obese, meta-analysis, subgroup Citation Zhang R, Hou Q, Li B, Deng L, Yang Y, Li T, Yao X, Yang L, Lin X, Liao Y, Wang L, Liu Y, Tan J, Wan Z and Shuai P (2023) Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials
This includes not rotating injection sites, which can cause skin irritation, redness, and swellingsome of the most common side effects
The timeline: what to expect and when Based on practitioner reports and the available clinical data, here is what the general timeline looks like for GLP-1 microdosing in autoimmune conditions
The authors declare that all data supporting the findings of this study are available within the article and the Supplementary Information